

A deadly dishonor roll

FDA-approved drugs withdrawn from market show fallibility of ‘gold standard’ clinical trials

Reports of safety and effectiveness from doctors who have monitored cannabis use by more than a million US citizens are dismissed by the government and the medical establishment with a simple assertion (that happens to be false): “There have been no randomized controlled trials.”

The reality is that there have been numerous RCTs confirming the safety and efficacy of cannabis in treating various conditions. Elsewhere in this issue Dr. Dustin Sulak refers to 11 RCTs of cannabis in the treatment of pain.

Randomized, placebo-controlled clinical trials are considered “the gold standard” in establishing the safety and effectiveness of a drug. The Food and Drug Administration relies solely on results from RCTs in approving products for the market.

Drug policy reformers often point out that the government has created huge hurdles for researchers who would study cannabis as medicine. But few question the infallibility of RCTs.

Some 35 drugs whose safety and efficacy were established in randomized, placebo-controlled trials to the satisfaction of the FDA have been removed from the market after patterns of harm emerged in the broader population. We are grateful to Pro-Con.org for listing them.

The FDA orders a manufacturer to stop selling a product “when its risks outweigh its benefits. A drug is usually taken off the market because of safety issues with the drug that cannot be corrected, such as when it is discovered that the drug can cause serious side effects that were not known at the time of approval.”

(It often turns out that a drug’s dangerous side effects were known to the manufacturer, but concealed from the FDA. Manufacturers don’t have to report the result of trials that show little benefit and/or recurrent adverse effects.)

Accutane (Isotretinoin)

Use: Acne
Manufacturer: Hoffman-La Roche
Years on the market: 27 (1982 to 2009)

Cause for recall: increased risk of birth defects, miscarriages, and premature births when used by pregnant women; inflammatory bowel disease; suicidal tendencies

More than 7,000 lawsuits were filed against the manufacturer over the side effects including a \$10.5 million verdict and two \$9 million verdicts.

Baycol (Cerivastatin)

Use: Cholesterol reduction



Manufacturer: Bayer A.G.

Years on the market: three (1998-2001)

Cause for recall: rhabdomyolysis (breakdown of muscle fibers that results in myoglobin being released into the bloodstream) which led to kidney failure; 52 deaths (31 in the US) worldwide; 385 nonfatal cases with most requiring hospitalization; 12 of the deaths were related to taking this drug in combination with gemfibrozil (Lopid).

Bextra (Valdecoxib)

Use: Pain relief
Manufacturer: G.D. Searle & Co.
Years on the market: 3.3 (2001-2005)

Cause for recall: Serious cardiovascular adverse events (death, heart attack, stroke); increased risk of serious skin reactions (like toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme); gastrointestinal bleeding.

The FDA determined that Bextra, a non-steroidal anit-inflammatory drug, showed no advantage over other NSAID pain relievers on the market.

Cylert (Pemoline)

Use: Central nervous system stimulant to treat ADHD/ADD
Manufacturer: Abbott Laboratories
On the market for 35 years (1975-2010)
Cause for recall: liver toxicity
The FDA added a box warning to Cylert in 1999, alerting doctors and patients to the potential of liver damage.

Darvon & Darvocet (Propoxyphene)

Use: Opioid pain reliever
Manufacturer: Xanodyneon
On the market 55 years (1955 to 2010)
Cause for recall: serious toxicity to the heart. Between 1981 and 1999 there were more than 2,110 deaths reported.

The UK banned Darvon and Darvocet in 2005. The FDA was petitioned in 1978 and

again in 2006 to ban the drug by the group Public Citizen.

DBI (Phenformin)

Use: antidiabetic
Manufacturer: Ciba-Geigy
On the market for 19 years (1959-1978)
Cause for recall: lactic acidosis (low pH in body tissues and blood and a buildup of lactate) in patients with diabetes.

7. DES (Diethylstilbestrol)

Use: synthetic estrogen to prevent miscarriage, premature labor, and other pregnancy complications
Manufacturer: Grant Chemical Company
On the market 31 years (1940 to 1971)
Cause for recall: clear cell adenocarcinoma (cancer of the cervix and vagina), birth defects, and other developmental abnormalities in children born to women who took the drug while pregnant; increased risk of breast cancer, higher risk of death from breast cancer; risk of cancer in children of mothers taking the drug including raised risk of breast cancer after age 40; increased risk of fertility and pregnancy complications, early menopause, testicular abnormalities; potential risks for third generation children (the grandchildren of women who took the drug).

Studies in the 1950s showed the drug was not effective at preventing miscarriages, premature labor, or other pregnancy complications.

Duract (Bromfenac)

Use: Pain killer
Manufacturer: Wyeth-Ayerst
On the market July 1997 through 1998
Cause for recall: 4 deaths; 8 patients requiring liver transplants; 12 patients with severe liver damage
Duract was labeled for maximum use of 10 days but patients often received/took more than 10 days worth of pills; all cases of death and liver damage involved patients taking pills for longer than 10 days.

Ergamisol (Levamisole)

Use: Worm infestation; colon and breast cancers; rheumatoid arthritis
Manufacturer: Janssen Pharmaceutica
On the market for 11 years (1989-2000)
Cause for recall: neutropenia (a type of low white blood cell count), agranulocytosis (a type of low white blood cell count), and thrombotic vasculopathy (blood clots in blood vessels) which results in retiform purpura (a purple discoloration of the skin that can sometimes require reconstructive

surgery)
Levamisole is still used to treat animals with worm infestations in the US. It is also being found in street cocaine as an adulterant to increase euphoric qualities.

Hismanal (Astemizole)

Use: Antipsychotic
Manufacturer: Janssen Pharmaceutica
On the market 11 years (1988-1999)
Cause for recall: slowed potassium channels in the heart that could cause torsade de pointes (TdP; a heart condition marked by a rotation of the heart’s electrical axis) or long QT syndrome (LQTS; prolonged QT intervals)

Lotronex (Alosetron)

Use: Irritable bowel syndrome (IBS) in women
Manufacturer: Prometheus Laboratories,
On the market less than a year (Feb. 9, to Nov. 28, 2000)
Cause for recall: 49 cases of ischemic colitis (inflammation and injury of the large intestine); 21 cases of severe constipation (10 requiring surgery); 5 deaths; mesenteric ischemia (inflammation and injury of the small intestine)
Lotronex was reintroduced to the US market in 2002 with restricted indication.

Meridia (Sibutramine)

Use: Appetite Suppressant
Manufacturer: Knoll Pharmaceuticals
On the market 13 years (1997 to 2010)
Cause for recall: increased cardiovascular and stroke risk.
FDA reviewer Dr. David Graham listed Meridia with Crestor, Accutane, Bextra, and Serevent as drugs whose sales should be limited or stopped because of their danger to consumers in Sep. 30, 2004 testimony before a Senate committee,

Merital & Alival (Nomifensine)

Use: Antidepressant
Manufacturer: Hoechst AG (now Sanofi-Aventis)
On the market three years (1982 to 1985)
Cause for recall: haemolytic anemia; some deaths due to immunohemolytic anemia

Micturin (Terodiline)

Use: Bladder incontinence
Manufacturer: Forest Labs
On the market two years (1989 to 1991)
Cause for recall: QT prolongation (irregular heartbeat) and potential for cardio-toxicity.

Cylert® (pemoline)

offers these benefits in a treatment program for MBD

- Single daily dose administration
- Minimal cardiovascular effects
- Mean dosage in long-term studies remained remarkably constant

EFFICACY
Multi-clinic study^{1,2}
21 investigators from 10 states and two provinces in Canada took part in the clinical studies.
Double-blind, placebo control
413 patients were randomly assigned to Cylert or placebo groups. 218 patients met all criteria for evaluation of efficacy.
Psychological test results
Children on Cylert had significantly higher scores statistically than those on placebo on these psychological tests:
• The Wechsler Intelligence Scale for Children (WISC) and its performance IQ Sub-Component
• The Wide Range Achievement Test (WRAT) (reading and arithmetic)
Overall results
Approximately two out of three patients were significantly improved by treatment with Cylert as reflected by global ratings.

1. Connors, C. K., et., Clinical Use of Stimulant Drugs in Children. Excerpta Medica, 1974, p. 98.
2. Page, J. G., et al., Learning Disabilities, 7:149, Oct., 1974.

Please see last page of this advertisement for Prescribing Information.

Importance of single daily dosage to the child, the parents and the teacher

For the child
No drug in child's possession while at school
Avoids situation in which child is repeatedly singled out as being "different"
Helps prevent the possible variations in effect caused by missed, forgotten or delayed doses

For the adults
Control of medication remains with parents
Obviates need for nurse or teacher to supervise taking of mid-day doses
Helps assure that the prescribed dosage is being given each day

Cylert (pemoline), alone among CNS stimulants used to treat MBD, is inherently long-acting, permitting once-daily dosage.

Cylert can be taken with meals
You can prescribe Cylert a.c., p.c., or with meals. Although the speed of absorption is slightly slowed by food, the total absorption is not affected.

When not to use Cylert
Cylert should not be used for (and will not be effective in) simple cases of overactivity in school-age children.
Neither should it be used in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.
The physician should rely on a complete history of the child and a thorough description of symptoms from both parents and teacher before postulating a diagnosis of MBD.

The three dosage strengths of Cylert (pemoline)

Cylert, 18.75 mg. (pink-coated, gloveless)	Cylert, 37.5 mg. (orange-coated, gloveless)	Cylert, 75 mg. (tan-coated, gloveless)
--	---	--

Tablets are actual size.

Description: Cylert (pemoline) is a white, tasteless, odorless powder which is relatively insoluble (less than 1 mg/ml) in water, chloroform, ether, acetone, and benzene. It is 95% ethyl alcohol, the solubility of pemoline is 2.2 mg/ml.

Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical symptoms have been observed, but mild to moderate

primary psychiatric disorders, including psychosis.
Contraindications: Cylert (pemoline) is contraindicated in patients with known hypersensitivity to any of its ingredients or to the drug. (See PRECAUTIONS)

Warnings: Cylert (pemoline) is a central nervous system stimulant. The pharmacologic activity of pemoline is similar to that of other known stimulants but with minimal sympathomimetic and mydriatic effects. Although the exact mode of pharmacodynamic action is undetermined, it may pemoline has been reported to increase the rate of fatness of dopamine in rat brain.
In human subjects, Cylert produces peak blood levels within 2-4 hours. The serum half-life is approximately 12 hours. Multiple dose studies in adults at several dose levels indicate that serum levels plateau in approximately three days. Cylert and its metabolites are primarily excreted in the kidneys with approximately 73% of an oral dose appearing in the urine within a 24-hour period. Approximately 41% of pemoline is excreted unchanged. Metabolites include pemoline diol, conjugated pemoline and monomelic acid.
Cylert (pemoline) has a gradual onset of action in children with minimal brain dysfunction. Using the recommended schedule of dosage titration, significant clinical benefit may not be evident until the third or fourth week of drug administration.

Indications: MINIMAL BRAIN DYSFUNCTION IN CHILDREN—An adjunctive therapy to other remedial measures (psychological, educational, social, and/or primary psychiatric disorders, including psychosis).
Special Diagnostic Considerations: Specific diagnosis of minimal brain dysfunction (MBD) is unknown, and therefore, no single diagnostic test is available. The diagnosis of MBD must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics.
Drug treatment is not indicated for all children with MBD. In the primary therapy of MBD, appropriate educational placement is essential and psychological intervention is generally necessary. When these measures alone are insufficient, the decision to use Cylert must be based upon the physician's assessment of the chronicity and severity of the symptoms. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis.

Drug Dependence: Studies of the drug abuse potential of Cylert (pemoline) in primates have not demonstrated a potential for self-administration. However, the pharmacologic similarities between Cylert and other CNS stimulants with known abuse liability suggest that drug dependence of the stimulant type might occur. There have been isolated reports of transient psychotic symptoms in adults following long-term use of Cylert (pemoline) taken only in excessive quantities. Therefore, caution should be observed in emotionally unstable patients considered to have a psychological potential for drug dependence.

Precautions: Delayed hypersensitivity reactions (including the liver) have been reported in 1-2% of the patients receiving Cylert equally after several months of therapy. No clinical

Withdrawn Drugs continued from previous page

Mylotarg (Gemtuzumab Ozogamicin)
Use: Acute myeloid leukemia (AML, a bone marrow cancer).
Manufacturer: Wyeth
On the market 10 years (2000-2010).
Cause for recall: increased risk of death and veno-occlusive disease (obstruction of veins).

Omniflox (Temaefloxacin)
Use: Antibiotic for pneumonia, bronchitis, and other respiratory tract infections; prostatitis and other genitourinary tract infections; skin ailments.
Manufacturer: Abbot Laboratories
On the market Jan. 31 to June 5, 1992
Cause for recall: three deaths; severe low blood sugar; hemolytic anemia and other blood cell abnormalities; kidney dysfunction (half of the cases required renal dialysis); allergic reactions including some causing life-threatening respiratory distress.

[The true extent of the damage caused by Omniflox and the vile duplicity of Abbot execs is laid out in a great book by Stephen Fried, “Bitter Pills.” See sidebar *WHERE*.]

Palladone (Hydromorphone hydrochloride, extended-release)
Use: Narcotic painkiller
Manufacturer: Purdue Pharma
On the market January to July 13, 2005
Cause for recall: high levels of palladone could slow or stop breathing, or cause coma or death; combining the drug with alcohol use could lead to rapid release of hydromorphone, in turn leading to potentially fatally high levels of drugs in the system

Permax (Pergolide)
Manufacturer: Valeant
On the market nine years (1988-2007)
Cause for recall: valve regurgitation (a condition that causes the valves to not close tightly, which allows blood to flow backward over the valve) in the mitral, tricuspid, and aortic heart valves, which can result in shortness of breath, fatigue, and heart palpitations
Permax is still available in the U.S. for veterinary use, specifically for pituitary pars intermedia hyperplasia or equine Cushing’s Syndrome (ECS) in horses.

Pondimin (Fenfluramine)
Use: Appetite suppressant
Manufacturer: Wyeth-Ayerst
On the market 24 years (1973 to 1997)
Cause for recall: 30% of patients prescribed the drug had abnormal echocardiograms; 33 cases of rare valvular disease in women; 66 additional reports of heart valve disease
Pondimin is better known as “Fen-Phen” when prescribed with Phentermine.

Posicor (Mibefradil)
Use: Calcium channel blocker (used to treat hypertension)
Manufacturer: Roche Laboratories
On the market 1 year (June ‘97 to June ‘98)
Cause for recall: fatal interactions with at least 25 other drugs, including common antibiotics, antihistamines, and cancer drugs) including astemizole, cisapride, terfenadine, lovastatin, and simvastatin
Posicor was found by the FDA to offer no significant benefit over other antihypertensive or antianginal drugs, which made the risks of drug interactions “unreasonable.” Patients immediately switching from Posicor to another calcium channel blocker were at increased risk of going into shock within 12 hours of the drug switch.

Propulsid (Cisapride)
Use: Severe nighttime heartburn associated with gastroesophageal reflux disease (GERD)
Manufacturer: Janssen Pharmaceutical
On the market seven years (1993-1970).
Cause for recall: more than 270 cases of



serious cardiac arrhythmias (including ventricular tachycardia, ventricular fibrillation, torsades de pointes, and QT prolongation) reported between July 1993 and May 1999, with 70 being deaths.
Propulsid is also banned in India (2011) and available for limited use in Europe. It is still available for use in animals in the US and Canada.

Quaalude (Methaqualone) Marketed as: Optimal, Sopor, Parest, Somnafac, and Bi-Phetamine T.
Use: Sedative and hypnotic
Manufacturer: William H. Rorer Inc. & Lemmon Company
On the market for 23 years (1962 to 1985)
Cause for recall: mania; seizures; vomiting; convulsions; death.
Methaqualone was originally tested in India as a malaria treatment (it was ineffective). The drug is now a schedule 1 drug in the United States (like heroin, marijuana, and LSD).

Raplon (Rapacuronium)
Use: Non-polarizing neuromuscular blocker (used in anesthesia)
Manufacturer: Organon Inc.
On the market for two years (1999-2001)
Cause for recall: bronchospasms and unexplained deaths
Raptiva (Efalizumab)
Use: Psoriasis
Manufacturer: Genentech
On the market six years (2003 to 2009)
Cause for recall: progressive multifocal leukoencephalopathy (PML; a rare and usually fatal disease that causes inflammation or progressive damage of the white matter in multiple locations of the brain)

Raxar (Grepafloxacin)
Use: Antibiotic for bacterial infections
Manufacturer: Glaxo Wellcome
On the market two years (1997 to 1999)
Cause for recall: cardiac repolarization; QT interval prolongation; ventricular arrhythmia (torsade de pointes)

Redux (Dexfenfluramine)
Use: Appetite suppressant
Manufacturer: Wyeth-Ayerst
On the market one year 1996-’97)
Cause for recall: 30% of patients prescribed the drug had abnormal echocardiograms; 33 cases of rare valvular disease in women; 66 additional reports of heart valve disease
Redux is better known as “Fen-Phen” when prescribed with Phentermine.

Rezulin (Troglitazone)
Use: Antidiabetic and anti-inflammatory
Manufacturer: Parke-Davis/Warner Lambert (now Pfizer)
On the market three years 1997 to 2000)
Cause for recall: at least 90 liver failures; at least 63 deaths
About 35,000 personal injury claims were

filed against the manufacturer (Pfizer).


Selacryn (Tienilic acid)
Use: blood pressure
Manufacturer: SmithKline
On the market three years (1979 to 1982)
Cause for recall: hepatitis; 36 deaths; at least 500 cases of severe liver and kidney damage
Anphar Labs (which developed the drug in France and sold rights to sell in US to SmithKline) sent a report to SmithKline in Apr. 1979 (translated in May 1979 to English from French) stating Selacryn damaged livers. On Dec. 13, 1984, SmithKline Beckman plead guilty to “14 counts of failing to file reports with the drug agency of adverse reactions to Selacryn and 20 counts of falsely labeling the drug with a statement that there was no known cause-and-effect relationship between Selacryn and liver damage”

Seldane (Terfenadine)
Use: Antihistamine
Manufacturer: Hoechst Marion Roussel (now Sanofi-Aventis)
On the market 13 years (1985 to 1998)
Cause for recall: life-threatening heart problems when taken in combination with other drugs (specifically erythromycin (an antibiotic) and ketoconazole (an antifungal)
Seldane was not considered an imminent threat. The FDA pulled Seldane from the market because Allegra and Allegra D were produced by the same company and were deemed safer by the FDA.

Trasylol (Aprotinin)
Use: antifibrinolytic to reduce blood loss during surgery
Manufacturer: Bayer
On the market 15 years (1993-2008)
Cause for recall: increased chance of death, serious kidney damage, congestive heart failure, and strokes
On Feb. 8, 2006, the FDA issued a public health advisory to surgeons who perform heart bypasses, alerting them of possible fatal side effects.

Vioxx (Rofecoxib)
Use: NSAID (pain relief)
Manufacturer: Merck
On the market 5.3 years (May 20, 1999 to Sep. 30, 2004)
Cause for recall: increased risk of heart attack and stroke; linked to about 27,785 heart attacks or sudden cardiac deaths between May 20, 1999 and 2003.
[The above from ProCon.org downplays the devastation caused by Vioxx. See sidebar *WHERE*.]

Xigris (Drotrecogin alfa, activated)
Use: Severe sepsis and septic shock
Manufacturer: Eli Lilly
On the market for 10 years (2001-2011)
Cause for recall: no survival benefit



Zelnorm (Tegaserod maleate)
Use: irritable bowel syndrome with constipation and chronic idiopathic constipation in women younger than 55.
Manufacturer: Novartis
On the market for 4.6 years (2002-2007)
Cause for recall: higher chance of heart attack, stroke, and unstable angina (heart/chest pain)
The FDA permitted restricted use of Zelnorm on an emergency basis (with prior case-by-case authorization from the FDA) on July 27, 2007.

Sources:
Abbott Laboratories, “Cylert,” American Journal of Diseases of Children, www.bonkersinstitute.org, 1976
Adforum.com, “Zelnorm - ‘N/A’ - Deutsch NY,” www.adforum.com (accessed Feb. 7, 2014)
AP, “Drug Maker Pleads Guilty over Lethal Side Effects,” www.nytimes.com, Dec. 14, 1984
AstraZeneca, “AstraZeneca Decides to Withdraw Exanta TM,” www.astrazeneca.com, Feb. 14, 2006
Michelle R. Carter and Sorour Amirhaeri, “p-ANCA-Associated Vasculitis Caused by Levamisole-Adulterated Cocaine: A Case Report,” Case Reports in Emergency Medicine, www.hindawi.com, 2013
Marlene Cimon, “Seldane Pulled for a Safer Allergy Drug,” www.latimes.com, Dec. 30, 1997
Dan Collins, “Insider: FDA Won’t Protect Public,” www.cbsnews.com, Dec. 7, 2004
Richard DeGrandpre, The Cult of Pharmacology: How America Became the World’s Most Troubled Drug Culture, 2006
“Drugs: The Dangers of Analgesics,” www.time.com, Feb. 24, 1967
Drugwatch, “What Is Accutane? It’s Uses and Interactions,” www.drugwatch.com/accutane, Dec. 10, 2013
Fairfield State Hospital, “Metrazol Therapy,” www.fairfieldstatehospital.com, Jan. 15, 2013
FDA, “FDA Alerts Consumers of Undeclared Drug Ingredients in Over-the-Counter Diabetes Product,” www.fda.gov, July 23, 2013
FDA, “FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen),” www.fda.gov, Sep. 15, 1997
FDA, “FDA Announces Voluntary Withdrawal of Pergolide Products: Agency Working with Product Manufacturers,” www.fda.gov, Mar. 29, 2007
FDA, “FDA Approves First Treatment for Women with Constipation-Predominant Irritable Bowel Syndrome,” www.web.archive.org, July 24, 2002
FDA, “FDA Drug Safety Communication: Voluntary Market Withdrawal of Xigris [drotrecogin alfa (activated)] Due to Failure to Show a Survival Benefit,” www.fda.gov, Oct. 25, 2011
FDA, “FDA Issues Public Health Advisory for Trasylol,” www.fda.gov, Feb. 8, 2006
FDA, “FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market,” www.fda.gov, June 21, 2010
FDA, “FDA Requests Marketing Suspension of Trasylol,” www.fda.gov, Nov. 5, 2007
FDA, “How Does FDA Decide When a Drug Is not Safe enough to Stay on the Market,” www.fda.gov, Jan. 7, 2010
FDA, “Information for Healthcare Profes-

